Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Feb;69(2):143-9.
doi: 10.1007/s00228-012-1320-8. Epub 2012 Jun 17.

Pharmacokinetics of transdermal buprenorphine patch in the elderly

Nabil Al-Tawil  1 , Ingegerd Odar-Cederlöf, Anna-Carin Berggren, Helen E Johnson, Jan Persson
Affiliations
Clinical Trial

Pharmacokinetics of transdermal buprenorphine patch in the elderly

Nabil Al-Tawil et al. Eur J Clin Pharmacol. 2013 Feb.

Abstract

Purpose: Transdermal buprenorphine patches provide comparable pain relief to that of low-potency opioids in elderly individuals. However, specific data on their use in elderly individuals is limited. This study investigated and compared the PK of buprenorphine transdermal patches in elderly (≥ 75 years) versus younger (50-60 years) individuals.

Methods: This was a multiple-dose, open-label, parallel-group study in healthy volunteers split into two age groups (younger, 50-60 years; elderly, ≥ 75 years) with 37 individuals in each. Study participants received two consecutive 7-day buprenorphine 5 μg/h transdermal patch applications, and blood samples were collected on the week of the second patch application [day 7 (predose), days 8, 9, 10, 12, and 14] to determine PK at steady state. Pharmacokinetic parameters were determined for buprenorphine and norbuprenorphine. Safety was assessed by analyzing adverse events, hematology, clinical chemistry, urine analysis, vital signs, electrocardiogram (ECG), and physical examinations.

Results: The area under the plasma concentration-time curve at steady state (AUC(tau)), measured over one dosing interval, was similar for elderly [mean ± standard deviation (SD) 9,940 pg/h/ml (4,827 pg/h/ml] and younger [mean ± SD 11,309 (3,670 pg/h/ml] individuals. Bioequivalence was not demonstrated between groups, which may be attributable to the relatively high level of variability in individual plasma profiles. More adverse events were reported by younger (216) than elderly (164) study participants.

Conclusions: No dosage alterations are necessary for PK reasons when treating elderly people with buprenorphine transdermal patches.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Mean plasma concentrations for buprenorphine for each group. Data points are mean ± standard error of the mean
Fig. 2
Fig. 2
Area under the plasma concentration-time curve at steady state (AUCtau) buprenorphine. Data points are individual participant values; the horizontal line represents the geometric mean for each population
See this image and copyright information in PMC

Comment in

References

    1. Wolf AD, Pfleger B. Bull WHO. 2003;81(9):646–56. - PMC - PubMed
    1. Swedish Medical Products Agency. (2004) Treatment of osteoarthritis [in Swedish]. 13:19-25
    1. NICE Clinical Guideline for care and management in adults – Osteoarthritis (http://www.scribd.com/doc/2663331/NICE-guideline - accessed October 2011)
    1. American Geriatric Society (AGS) Panel on pharmacological management of persistent pain in older persons. J Am Geriatc Soc. 2009;67:1331–46. - PubMed
    1. The Swedish Council on Technology Assessment in Healthcare. (2009) Pharmaceutical treatments among the elderly – how can it be improved? [in Swedish]. Stockholm, Sweden: Swedish Council on Technology Assessment in Healthcare (www.sbu.se)

Publication types

LinkOut - more resources